Grade III Astrocytic Tumor

A grade III astrocytic tumour is a cancer that starts from star-shaped support cells in the brain called astrocytes. On a microscope slide, the cells look more crowded and more aggressive than lower-grade tumours, and doctors can see active cell division (mitoses). Today, doctors use modern lab tests on the tumour tissue and usually name this tumour “astrocytoma, IDH-mutant, CNS WHO grade 3.” The “IDH-mutant” part is important—it means the tumour carries a change in one of the IDH genes (IDH1 or IDH2). This name comes from the 2021 (and ongoing) World Health Organization classification, which groups these tumours by their molecular features as well as by how the cells look. In older systems, the same tumour was often called “anaplastic astrocytoma (WHO grade III).” PMC+2Nature+2

A grade III astrocytic tumor is a fast-growing brain tumor that starts from star-shaped support cells called astrocytes. In the newest WHO brain-tumor system, most tumors that used to be called “anaplastic astrocytoma (grade III)” are now classified by their DNA features and named “astrocytoma, IDH-mutant, grade 3.” This means the tumor usually has a change in the IDH gene, grows faster than grade 2, and needs treatment after surgery. If there is dead tissue (necrosis) or many new blood vessels, it is grade 4, not grade 3. PMC+2PMC+2

This tumour is diffuse, which means it sends microscopic fingers into nearby brain tissue. That is why even skilled surgery cannot remove every last cell. Grade 3 tumours grow faster than grade 2 and can progress to a higher grade if not controlled. However, they are not the same as glioblastoma (which is usually IDH-wildtype and is grade 4 by definition). Radiopaedia+1

Other names

• Anaplastic astrocytoma (WHO grade III) – older, widely used name.

• Astrocytoma, IDH-mutant, CNS WHO grade 3 – current, preferred name in WHO 2021+.

• High-grade astrocytoma (grade 3) – descriptive term used in clinics.

• Diffuse astrocytoma, grade 3 – older wording that emphasized spread.

These names refer to the same biological idea: a diffuse astrocytic tumour with grade-3 behaviour and, under today’s rules, usually proven IDH mutation and no 1p/19q codeletion (that codeletion would instead define an oligodendroglioma). PMC+1

Types

Even within grade 3, doctors talk about “types” in three practical ways:

1. By molecular profile (most important today)

   • IDH1-mutant vs IDH2-mutant: both count as “IDH-mutant,” but the exact gene may matter for prognosis or trials.

   • ATRX loss (by immunohistochemistry) and TP53 mutation: common in IDH-mutant astrocytomas and help confirm the diagnosis (ATRX loss and 1p/19q codeletion rarely occur together).

   • MGMT promoter methylation: doesn’t define the type, but it helps predict response to alkylating chemotherapy (like temozolomide). New England Journal of Medicine+3PMC+3Oncoscience+3

2. By location

   • Supratentorial (cerebral hemispheres) – the most common.

   • Deep or eloquent areas (e.g., speech or motor regions) – critical for planning safe surgery.

   • Spinal cord – uncommon but possible. (Location shapes symptoms and treatment planning.) ABTA

3. By clinical behaviour

   • Newly diagnosed grade 3 vs progressed from a lower-grade astrocytoma (malignant transformation). Progression risk rises with time in untreated or partially treated lower-grade tumours. AANS

Causes

Most patients do nothing to cause this tumour. For many, the exact cause remains unknown. Still, science has identified several risk factors and biological drivers that can contribute. Items below are written in simple English and reflect associations or mechanisms; having a risk factor does not mean you will get a tumour.

1. IDH gene mutation (IDH1/IDH2): a key early change that shapes how the tumour behaves and how it’s named today. PMC

2. TP53 gene change: a common partner mutation in IDH-mutant astrocytomas that helps tumour cells bypass normal growth checks. PMC

3. ATRX gene loss: affects how DNA packages in the cell and helps the tumour keep its chromosome ends (telomeres) stable. Oncoscience+1

4. MGMT promoter unmethylated status (biologic resistance): not a cause of starting the tumour, but a reason some tumours resist temozolomide; included here as a driver of behaviour. PMC

5. Prior ionizing radiation to the head (especially in childhood): a rare but proven environmental cause for later gliomas. AANS

6. Inherited Li-Fraumeni syndrome (TP53): raises risk of multiple cancers including astrocytoma. AANS

7. Neurofibromatosis type 1 (NF1): increases risk of gliomas, especially optic pathway tumours; occasionally astrocytomas elsewhere. AANS

8. Turcot syndrome (APC or mismatch repair genes): linked with colorectal cancer and certain brain tumours, including astrocytoma/glioblastoma. AANS

9. Tuberous sclerosis complex: associated with subependymal giant cell astrocytoma; shows that germline changes can drive astrocyte tumours. AANS

10. Age: these tumours are more often seen in adults than in young children; patterns differ by grade and IDH status. Cleveland Clinic

11. Male sex: some series show a slight male predominance among diffuse gliomas. (Epidemiology varies by subtype.) ABTA

12. Family history of glioma: uncommon, but families with multiple gliomas suggest shared genetic risk in a minority of cases. Cancer.gov

13. Vinyl chloride exposure (possible risk): suggested for glioma broadly; evidence is limited. Cancer.gov

14. Immune escape biology: tumours evolve ways to turn off immune attack, enabling growth (mechanistic driver rather than a lifestyle cause). AANS

15. Malignant transformation from a lower-grade astrocytoma: over time, a grade 2 can acquire new mutations and become grade 3. AANS

16. CDKN2A/B deletion (progression factor): when present, it can mark or drive more aggressive behaviour; in IDH-mutant tumours, homozygous loss upgrades to grade 4. ScienceDirect

17. Epigenetic changes (like DNA methylation shifts): these changes re-program cells and can support tumour growth and drug resistance. PMC

18. No convincing proof for mobile phones: heavy use has been studied; current evidence does not show a causal link. AANS

19. No strong link to routine infections: unlike primary CNS lymphoma (EBV-related), common infections are not known causes of astrocytoma. Cancer.gov

20. Most cases are sporadic: for the majority, no specific external cause is identified. AANS

Symptoms

1. Headache that gets worse over weeks: often dull, sometimes worse in the morning; pressure builds as the tumour grows. ABTA+1

2. Seizures (fits): a common first sign of diffuse gliomas; may be focal (one arm jerks) or generalized. ABTA

3. Nausea or vomiting: can occur with raised pressure inside the skull. Mayo Clinic

4. Personality or mood changes: family may notice irritability, apathy, or depression. ABTA

5. Thinking and memory problems: trouble concentrating, planning, or making decisions. ABTA

6. Weakness or clumsiness on one side: the tumour can affect the motor pathways. ABTA

7. Numbness or altered sensation: pins-and-needles or reduced feeling. ABTA

8. Speech problems: word-finding difficulty or slurred speech if language areas are involved. ABTA

9. Vision changes: blurred or double vision; sometimes loss of part of the visual field. AANS

10. Balance problems or unsteady gait: the tumour can disturb coordination pathways. Mayo Clinic

11. Confusion or drowsiness: especially with larger tumours and swelling. Mayo Clinic

12. Headache waking you from sleep: can signal increased intracranial pressure. AANS

13. Behavioral disinhibition or lack of initiative: more common with frontal lobe involvement. ABTA

14. Difficulty swallowing or facial weakness: if the tumour affects specific cranial nerve pathways. MedlinePlus

15. Back or limb weakness with spinal involvement: rare spinal astrocytomas can cause progressive weakness or numbness. Mayo Clinic

Diagnostic tests

A) Physical examination (bedside checks)

1. Full neurological examination: your clinician checks mental status, cranial nerves, strength, sensation, reflexes, coordination, and gait to figure out which brain area might be involved. This is painless and guides which scans and specialists you need. MedlinePlus+1

2. Cranial nerve exam: shining a light in the eyes, testing facial movement and feeling, hearing, tongue movement, and swallow—this helps localize the tumour’s effects on brain pathways. TeachMeSurgery

3. Motor strength and muscle tone testing: pushing and pulling against resistance, checking for abnormal reflexes, and looking for drift or spasticity—these findings map where the tumour presses or invades. NYU Langone Health

4. Sensation testing: light touch and pinprick help detect pathways disturbed by the tumour. TeachMeSurgery

5. Coordination and gait tests (finger-to-nose, heel-to-shin, Romberg): simple bedside maneuvers that pick up cerebellar or proprioceptive problems from tumour or swelling. Stroke Manual

6. Mental status and cognition screening (e.g., quick bedside tools): short tasks check attention, memory, and language; results inform whether to order fuller neuropsychologic testing. AMBOSS

7. Fundoscopy (looking at the optic discs): doctors look for papilledema (swelling of the optic nerve head), a clue to raised intracranial pressure from tumour and swelling. MedlinePlus

8. Vital signs and general exam: blood pressure, weight, and overall health matter because they affect treatment safety (e.g., surgery or chemo tolerance). (Clinical practice standard.) Cancer.gov

B) Manual tests (focused bedside maneuvers/tools)

9. Visual field confrontation test: checks for blind spots caused by tumours near optic pathways. It takes a minute and needs no machines. NYU Langone Health

10. Language assessment (naming, repetition, fluency): a brief, structured talk with the clinician can localize a left-hemisphere language area tumour. AMBOSS

11. Pronator drift test: arms held out, palms up; the weaker arm drifts—this is a sensitive sign of mild motor pathway weakness. Stroke Manual

12. Reflex testing with a hammer (including Babinski sign): helps determine if a long motor pathway is irritated by the tumour. NYU Langone Health

13. Bedside memory and attention tests: repeating words, serial 7s, or digit spans help quantify cognitive impact and guide referrals. AMBOSS

C) Laboratory & pathological tests (the diagnostic “gold standard”)

14. Stereotactic biopsy or surgical specimen with H&E histology: shows increased cell density, nuclear atypia, and mitoses consistent with a grade 3 astrocytic tumour. Tissue is required for a definitive diagnosis. ABTA

15. IDH1-R132H immunohistochemistry (and sequencing for non-R132H variants): confirms the key IDH-mutant status for naming and prognosis. PMC

16. ATRX immunohistochemistry: loss of nuclear ATRX supports astrocytoma (and argues against oligodendroglioma). Oncoscience

17. TP53 (p53) immunohistochemistry or sequencing: frequent alterations back up the diagnosis and help with classification. PMC

18. 1p/19q codeletion testing (FISH/NGS): performed to exclude oligodendroglioma; if codeleted, the diagnosis changes. PMC

19. MGMT promoter methylation testing: predicts how well alkylating chemotherapy (like temozolomide) might work; also carries prognostic value. PMC+1

20. Proliferation index (Ki-67/MIB-1): helps estimate how fast the tumour is cycling; higher values often correlate with higher grade. (Used alongside other features.) Wiley Online Library

Other panels (when available) can include CDKN2A/B status (relevant to upgrading to grade 4 in IDH-mutant astrocytoma), TERT promoter mutation (more typical of IDH-wildtype glioblastoma), and broader NGS panels for trials. ScienceDirect

D) Electrodiagnostic tests

21. EEG (electroencephalogram): records brain waves if you have seizures; helps classify seizure type and guide anti-seizure treatment. It’s non-invasive and commonly used after a first seizure. American Academy of Neurology+1

22. Evoked potentials / intraoperative neurophysiologic monitoring: during surgery near critical pathways (movement, sensation, vision), these tests help surgeons avoid damage while removing tumour. AANS

E) Imaging tests

23. MRI of the brain with and without contrast (core test): shows the tumour and surrounding swelling. Contrast enhancement is more likely in higher-grade lesions, but absence of enhancement does not rule out grade 3. AANS

24. T2/FLAIR sequences: highlight the diffuse, infiltrative zone—the “finger-like” spread that cannot be fully seen on standard T1 images. Radiopaedia

25. Diffusion-weighted imaging (DWI/ADC): assesses cell density; lower ADC can suggest higher tumour grade. PMC

26. Perfusion MRI (DSC/DCE): measures blood volume and leakiness; higher perfusion can point to higher grade or active tumour. PMC

27. MR spectroscopy: looks at brain chemicals (e.g., high choline, low NAA) to support the diagnosis and to plan biopsy targets. AANS

28. Functional MRI (fMRI) and diffusion tractography (DTI): map language and motor areas and important white-matter tracts to plan a safer surgery. AANS

29. CT head (often first in emergencies): quickly detects mass effect or bleeding; MRI still provides the detail. Cancer.gov

30. PET imaging (amino-acid PET such as FET, or FDG when available): can help define tumour extent, guide biopsy to the most active area, and sometimes help tell recurrence from treatment-related change after radiation. It complements advanced MRI rather than replacing it. Journal of Nuclear Medicine+2Frontiers+2

Non-pharmacological treatments (therapies & others)

The items below are supportive or tumor-directed but not “drug medicines.” Your oncology team personalizes them to your tumor genetics, age, and function.

1. Maximal safe surgical resection. The first treatment is usually surgery to remove as much tumor as safely possible. It reduces pressure, provides tissue for the correct diagnosis, and improves outcomes when followed by radiotherapy and chemotherapy. Surgeons use tools like neuronavigation, mapping, and fluorescence to protect language and motor areas. Nature

2. Post-operative radiotherapy. Standard brain radiotherapy for grade 3 astrocytoma is typically 54–60 Gy in 1.8–2.0 Gy daily fractions to the involved area, planned on MRI. It kills tumor cells left after surgery and reduces the chance of early regrowth. PMC+1

3. Advanced radiation planning. Modern contouring and dose-planning guidelines (ESTRO-EANO 2025) help target tumor and microscopic spread while protecting healthy brain to lower side effects like fatigue, memory trouble, or hair loss. The Green Journal+1

4. Stereotactic biopsy (when resection isn’t safe). A needle biopsy guided by imaging confirms the diagnosis and allows molecular testing (IDH, ATRX, MGMT), which directs further care. PMC

5. Corticosteroid management for brain swelling. Dexamethasone reduces edema and relieves headache, nausea, or weakness. Typical starting doses for symptomatic mass effect are 4–8 mg/day, titrated to symptoms and tapered as soon as possible to limit harm. PMC+2PMC+2

6. Seizure care and safety. If you have seizures, anti-seizure medicine is used; if you have no seizures, experts do not recommend routine preventive anti-seizure drugs. Your team also teaches sleep, driving, and safety steps. PMC

7. Neuro-rehabilitation. Physical, occupational, and speech therapy help with strength, balance, walking, speaking, swallowing, and daily activities during and after treatment. Exercise programs are safe and improve fatigue and quality of life in cancer. PubMed+1

8. Cognitive rehabilitation. Structured brain-training and compensatory strategies (notes, alarms, spaced practice) can support memory and attention after surgery or radiotherapy. PubMed

9. Psychological support. Counseling, peer groups, and mindfulness or relaxation training help anxiety, low mood, and sleep. Psychological care improves coping and treatment adherence. PubMed

10. Nutritional counseling. A registered dietitian helps maintain weight and muscle, handles taste changes and nausea, and teaches food safety when immunity is low. Focus is on balanced intake rather than high-dose supplements. American Cancer Society

11. Fatigue management and energy pacing. Scheduled rest, light activity, and sleep hygiene reduce cancer-related fatigue and daytime sleepiness. PubMed

12. Headache management (non-drug options). Hydration, regular sleep, stress control, cold/warm packs, and trigger tracking may reduce attacks alongside medical care. American Cancer Society

13. Edema-aware positioning & mobility. Keeping the head slightly elevated and avoiding prolonged straining can ease pressure symptoms in some patients, combined with medical therapy. eviQ

14. Return-to-work and driving assessments. Specialists evaluate attention, visual fields, and reaction time to guide safe return to duties and driving laws. PubMed

15. Palliative and supportive care early. Symptom-focused care (pain, mood, sleep, spiritual needs) started early improves quality of life and caregiver support. PubMed

16. Caregiver education. Teaching families about seizures, steroid side effects, and urgent warning signs reduces emergency visits and improves home safety. WUTH

17. Exercise therapy. Regular walking and light resistance training (as tolerated) help stamina, mood, and function during and after treatment. PubMed

18. Dietary pattern coaching. A plant-forward pattern (vegetables, fruits, whole grains, legumes, nuts) with lean proteins supports overall health; there is no proven anti-glioma “miracle diet.” American Cancer Society+1

19. Device-based care (case-by-case). Tumor Treating Fields are established for glioblastoma; in grade 3 astrocytoma this is not standard and generally considered only in trials or special circumstances. Ask your team. Nature

20. Clinical trials. Trials test new drugs (including IDH-targeted agents and vaccines), radiation schedules, and rehab strategies; ask your center about options. U.S. Food and Drug Administration+1

---

Drug treatments

Important: Doses below are typical label or guideline starting points and not personal medical advice. Final dose/timing/combos must be set by your oncology team based on labs, side-effects, and your goals.

1. Temozolomide (TMZ). Class: Alkylating agent. Dose/time: Common adjuvant schedule is 150–200 mg/m² once daily for 5 days every 28 days, usually for 6–12 cycles, with anti-nausea meds and blood-count checks. Purpose: Kills dividing tumor cells; proven survival benefit as adjuvant after RT in IDH-mutant grade 3. Mechanism: Methylates DNA (O6-guanine). Side effects: Low blood counts, nausea, fatigue, rare pneumocystis risk. FDA Access Data+2FDA Access Data+2

2. PCV regimen (Procarbazine, Lomustine/CCNU, Vincristine). Class: Combined chemo. Dose/time: Typical PCV cycle: lomustine 110 mg/m² day 1, procarbazine 60 mg/m² days 8–21, vincristine IV days 8 and 29, repeated q6–8 weeks. Purpose: Alternative to TMZ; used after RT in select IDH-mutant tumors. Mechanism: DNA alkylation + mitotic arrest. Side effects: Myelosuppression, neuropathy (vincristine), nausea, rare lung/liver toxicity. PMC+2cancercare.mb.ca+2

3. Carmustine (IV). Class: Nitrosourea. Purpose: Option at recurrence or in multi-agent plans. Mechanism: Cross-links DNA. Side effects: Low blood counts, lung/liver toxicity. Nature

4. Carmustine wafer (GLIADEL). Class: Local nitrosourea implant placed during surgery. Dose: Up to 8 wafers (61.6 mg total) placed in the resection cavity. Purpose: Delivers chemo directly to the tumor bed. Side effects: Wound problems, infection, brain swelling. FDA Access Data+1

5. Bevacizumab (for symptomatic recurrence/edema). Class: Anti-VEGF antibody. Purpose: Not shown to extend life in grade 3, but can reduce edema and steroid needs at recurrence or radiation necrosis. Mechanism: Blocks VEGF to reduce leaky vessels. Side effects: High blood pressure, bleeding, clots, poor wound healing. PubMed

6. Procarbazine (single agent). Sometimes used alone in patients who cannot tolerate combinations. Risks: MAOI-like interactions and dietary restrictions. PMC

7. Lomustine (single agent). Often used at recurrence if prior TMZ given. Risks: Prolonged bone-marrow suppression; need spacing between cycles. PMC

8. Vincristine (component of PCV). Mechanism: Microtubule inhibitor. Risks: Peripheral neuropathy and constipation; dosing capped in older adults. PMC

9. Dexamethasone (symptom control). Class: Corticosteroid. Purpose: Shrinks edema to rapidly relieve headaches, nausea, weakness; taper ASAP. Common start: 4–8 mg/day and individualize. Risks: High sugar, infection, mood/sleep changes, muscle loss. PMC

10. Levetiracetam (seizures). Class: Antiepileptic. Purpose: Treats actual seizures; not used routinely if you never had a seizure. Risks: Irritability, fatigue (varies). PMC

11. Ondansetron (anti-nausea). Class: 5-HT3 blocker. Purpose: Prevents chemo-related nausea during TMZ/PCV. Risks: Constipation, headache, QT-prolongation in some. FDA Access Data

12. PJP prophylaxis (e.g., TMP-SMX) when indicated. Purpose: In selected patients on prolonged high-dose steroids or combined chemoradiation. Risks: Allergy, low counts—your team decides need and duration. FDA Access Data

13. Gastric protection (PPI/H2 blocker) with steroids. Purpose: Lowers ulcer risk while on dexamethasone; use only as needed. WUTH

14. Vorasidenib (IDH inhibitor)—approved for IDH-mutant grade 2 glioma; not standard for grade 3 yet but relevant in trials/selected cases. Mechanism: Inhibits mutant IDH to reduce oncometabolite 2-HG. Note: Discuss clinical trial access for grade 3. U.S. Food and Drug Administration+1

15. PCV → TMZ sequencing strategies. Teams may choose PCV or TMZ based on age, MGMT status, and tolerance; both options appear in major guidelines. btrt.org

16. Aprepitant/netupitant (NK-1 blockers) as needed for highly emetogenic regimens or sensitive patients. Purpose: Strong anti-nausea support. PMC

17. Growth-factor support (filgrastim/pegfilgrastim) when chemo causes severe neutropenia; this prevents infections and keeps cycles on time. (See “immunity support” section for details.) PMC

18. Pain medicines (step-wise from acetaminophen to short opioid courses if needed) to keep function and sleep. Use cautiously with seizure meds. American Cancer Society

19. Management of radiation necrosis (steroids; sometimes bevacizumab) if later scans show treatment-related swelling rather than tumor. PubMed

20. Clinical-trial agents (e.g., vaccines, checkpoint inhibitors in select biomarker contexts): discuss at major centers; evidence in grade 3 remains evolving. Nature

---

Dietary molecular supplements

Strong cancer groups advise food-first nutrition. High-dose antioxidant pills during chemo/radiation can interfere with treatment. Use supplements only for deficiencies or specific goals agreed by your team.

1. Vitamin D (correct deficiency only). Helps bone and muscle during steroids/less activity. Typical repletion per labs; do not mega-dose. Note: No proof it treats astrocytoma. American Cancer Society

2. Omega-3 fatty acids (EPA/DHA). May help appetite, weight maintenance, and inflammation in some cancer settings; evidence is mixed; use food sources first (fish, walnuts). Dose: Often 1–2 g/day combined EPA/DHA if approved. PMC+1

3. Protein (whey/pea) if intake is poor. Supports muscle during treatment-related fatigue; choose tested products to avoid contaminants. American Cancer Society

4. Probiotics (case-by-case). May help antibiotic-related diarrhea; avoid if neutropenic or immunocompromised without doctor approval. American Cancer Society

5. Melatonin (sleep aid; experimental anticancer signals). Small and older studies suggest possible synergy with radiotherapy in gliomas, but evidence is not definitive; discuss interactions. Typical sleep doses: 2–5 mg nocte. PubMed+1

6. Ginger (nausea). Food-based ginger can ease mild nausea; supplements may interact with blood thinners. American Cancer Society

7. Magnesium (only if low). Helps cramps/constipation from meds; monitor levels; high doses can cause diarrhea. American Cancer Society

8. B-complex (if labs or diet show shortfall). Avoid high-dose single B vitamins unless prescribed. American Cancer Society

9. Multivitamin at RDA levels if intake is limited; avoid “mega” antioxidant formulas during radiation/chemo. Oncolink+1

10. Creatine (selected rehab cases). Limited data; sometimes used short-term to support strength during rehab; must be cleared for kidney function and interactions. PubMed

---

Immunity-support / regenerative / stem-cell–related drugs

These medicines do not treat the tumor, but they help your body tolerate treatment or are used in special transplant settings.

1. Filgrastim (G-CSF). Stimulates white-blood-cell recovery after chemo to reduce infection risk; dose is weight-based daily injections until counts recover. PMC

2. Pegfilgrastim. Long-acting once-per-cycle G-CSF to prevent neutropenia with myelosuppressive regimens. PMC

3. Epoetin alfa (EPO). Treats chemo-related anemia in selected patients to reduce transfusions; used cautiously because of clot risk; target hemoglobin is individualized. ACS Journals

4. Eltrombopag or Romiplostim. Platelet growth agents used rarely if severe thrombocytopenia limits therapy; only with specialist oversight due to clot and liver risks. ACS Journals

5. Palifermin. Epithelial growth factor used with high-dose chemotherapies to reduce mouth sores—mainly in transplant settings; uncommon in glioma. ACS Journals

6. Autologous stem-cell transplant (concept + mobilizers). In children or selected trials for relapsed high-grade glioma, high-dose chemo with stem-cell rescue has been used; not routine in adults. Mobilization uses G-CSF ± chemo. NCBI

---

Surgeries

1. Awake-mapping craniotomy for maximal safe resection. The team removes visible tumor while testing language/movement live to avoid harm. Improves control and gives tissue for accurate molecular typing. Nature

2. Standard craniotomy with neuronavigation. For tumors outside critical speech/motor areas, image guidance assists precise removal. Nature

3. Fluorescence-guided surgery (e.g., 5-ALA). The tumor glows to help surgeons see margins more clearly and improve extent of resection. Nature

4. Stereotactic biopsy. When removal is unsafe (deep or diffuse tumors), a small needle sample confirms the exact type and genes to direct therapy. PMC

5. Carmustine wafer placement (GLIADEL). After resection, surgeons can place local chemo wafers into the cavity as an adjunct in selected high-grade gliomas. FDA Access Data

---

Preventions

There is no proven way to prevent an astrocytic tumor. But you can lower treatment complications and support overall health by: (1) following your oncologist’s plan; (2) keeping all scan/blood-test visits; (3) taking seizure and steroid instructions seriously; (4) practicing food safety when counts are low; (5) walking or exercising as you are able; (6) using a plant-forward diet; (7) not smoking; (8) moderating alcohol; (9) sleeping regularly; (10) asking about vaccines (flu, COVID) at safe times during treatment. American Cancer Society+2American Cancer Society+2

---

When to see a doctor urgently

Go or call now if you have new or worsening severe headache, repeated vomiting, a new seizure, sudden weakness or numbness on one side, trouble speaking, confusion, high fever or chills on chemo, or rapidly worsening vision. These can mean swelling, bleeding, infection, or tumor growth and need urgent care. PMC

---

What to eat and what to avoid

1. Eat regularly with balanced meals and snacks so you keep energy and weight. American Cancer Society

2. Prioritize plants: vegetables, fruits, whole grains, legumes, nuts; add lean proteins and healthy oils. American Cancer Society

3. Include protein at each meal (fish, eggs, poultry, yogurt, tofu, beans) to protect muscle during treatment. American Cancer Society

4. Hydrate; keep water handy; use oral rehydration or broths on tough days. American Cancer Society

5. Food safety: wash produce well; avoid raw/undercooked meats and unpasteurized foods when counts are low. American Cancer Society

6. Limit added sugars and ultra-processed foods—good for overall health even if not glioma-specific. American Cancer Society

7. Do not start high-dose antioxidant supplements during chemo/radiation unless your oncology team approves. Oncolink+1

8. Caffeine/coffee/tea: no clear link with glioma risk; moderate intake is fine unless it worsens sleep or interacts with meds. Frontiers+1

9. Red/processed meats: general cancer prevention advice favors moderation; data for glioma are inconsistent—focus on overall healthy patterns. PMC+1

10. Alcohol: keep low; it can worsen sleep and interact with medicines. Follow your care team’s advice. American Cancer Society

---

Frequently Asked Questions

1. Is “grade III astrocytoma” the same as “anaplastic astrocytoma”?
   Yes. The older term is anaplastic astrocytoma. Today many are called astrocytoma, IDH-mutant, grade 3 in WHO 2021. PMC

2. What treatments work best after surgery?
   For most IDH-mutant grade 3 astrocytomas, radiotherapy followed by adjuvant temozolomide is standard based on the CATNON trial. Some centers consider RT→PCV. PMC+1

3. Do I need chemo at the same time as radiation?
   In CATNON, concurrent TMZ did not improve survival in IDH-mutant tumors; the benefit was from adjuvant TMZ after RT. Your team individualizes this. PMC

4. How is grade 3 different from grade 4 (glioblastoma)?
   Grade 4 shows necrosis and/or microvascular proliferation and behaves more aggressively; many IDH-wildtype high-grade tumors meet GBM criteria. PMC

5. Which genes matter?
   IDH mutation defines the tumor type; ATRX loss and TP53 changes support astrocytoma; 1p/19q codeletion is absent (that would be oligodendroglioma). MGMT methylation helps predict TMZ sensitivity. PMC

6. Will I need steroids?
   Often briefly for swelling symptoms. Start low (e.g., 4–8 mg/day dexamethasone) and taper as soon as safe to reduce side effects. PMC

7. Should I take anti-seizure pills if I never had a seizure?
   No. Guidelines say do not use prophylactic anti-seizure drugs in seizure-free brain-tumor patients. PMC

8. Are chemo wafers useful?
   Carmustine wafers can be placed during surgery for some high-grade gliomas; benefits are modest and risks exist. Discuss at a high-volume center. Nature+1

9. What about IDH-inhibitor pills?
   Vorasidenib is FDA-approved for grade 2 IDH-mutant gliomas. For grade 3, usage is mainly in trials or special cases. Ask about studies. U.S. Food and Drug Administration

10. Do vitamins or antioxidants help treat the tumor?
    No proven benefit; high-dose antioxidant supplements may even blunt radiation/chemo effects. Use supplements only for documented needs with your team’s OK. Oncolink+1

11. Is there a special anti-cancer diet for astrocytoma?
    No single diet cures brain tumors. A plant-forward, balanced pattern supports strength and recovery. American Cancer Society

12. Can exercise help me during treatment?
    Yes. Aerobic plus light resistance exercise improves fatigue, function, mood, and quality of life when tailored to your abilities. PubMed

13. How often will I need scans?
    Your team schedules surveillance MRI (often every 2–4 months at first). The exact timing depends on symptoms, treatment phase, and prior results (clinic-specific). btrt.org

14. What are red-flag symptoms to call about?
    New severe headache, repeated vomiting, sudden weakness, new seizures, confusion, high fever, or rapidly worsening vision. PMC

15. Where can I read more patient-friendly guidance?
    The NCI PDQ and NCCN Patient Guidelines offer reliable overviews of high-grade gliomas. Cancer.gov+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 16, 2025.